(RTTNews) - Lexaria Bioscience Corp. (LEXX), a global leader in drug delivery technology, announced on Wednesday that it has received approval from the independent ethics board for its GLP-1-H25-5 human pilot study.
The study will test an oral version of liraglutide, formulated using Lexaria's proprietary DehydraTECH technology, comparing its safety and pharmacokinetic performance to the currently available injectable liraglutide or Saxenda.
This trial builds on positive results from a previous rodent study where DehydraTECH-liraglutide demonstrated superior performance over semaglutide in reducing weight (5.88%) and blood sugar (11.54%).
The upcoming human study will involve 8-10 healthy volunteers, aiming to demonstrate the efficacy of oral DehydraTECH-liraglutide. If successful, this pilot study could lead to a future Phase I registered trial.
Lexaria's DehydraTECH platform has shown promising results in enhancing the bio-absorption of several GLP-1 drugs, including liraglutide, semaglutide, and tirzepatide, which are widely used for weight loss and diabetes management. The company will provide further updates as the study progresses.
Currently, LEXX is trading at $2.01 up by 4.15%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
